Human Psychopharmacology: Clinical and Experimental最新文献

{"title":"The Impact of Citicoline/Phosphatidylserine Supplementation on Cognitive Performance and Executive Functions in Mental Disorders: A Systematic Review of Controlled Trials","authors":"Nazan Gundogan Kucuksahin,&nbsp;Tugce Turan Kaya,&nbsp;Eren Halac,&nbsp;Ekin Sut,&nbsp;Remzi Ogulcan Ciray","doi":"10.1002/hup.70058","DOIUrl":"https://doi.org/10.1002/hup.70058","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Citicoline and phosphatidylserine (PS) have been proposed as potential neuroprotective and cognitive-enhancing agents; however, evidence of their therapeutic impact across populations with mental disorders remains limited. This systematic review aimed to evaluate the effects of citicoline and PS, administered as monotherapy or adjunctive treatment, on cognitive performance in children, adolescents, and adults with mental disorders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review of 11 included studies was conducted following PRISMA guidelines. Databases searched were PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL through October 2025. Ten studies were randomized controlled trials (RCTs), and one was a non-randomized controlled trial (non-RCT). Methodological quality and risk of bias were evaluated using the RoB 2 and ROBINS-I tools.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Five studies focused on children with ADHD, and the remaining studies included adults with mood disorders, alcohol and substance use disorders, and schizophrenia. Regarding ADHD, PS-containing supplementation produced significant improvements in attention and impulsivity in three studies, whereas two studies found no significant differences. A single study in schizophrenia reported significant improvements in verbal free recall but no global cognitive gains. Results for alcohol and substance use disorders, as well as mood disorders were mixed. Two studies revealed selective benefits in cognitive performance, while the others showed none. Overall, findings were heterogeneous and inconsistent across diagnostic groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Given methodological limitations and high risk of bias, current evidence does not support citicoline or PS-containing compounds as effective cognitive enhancers in mental disorders. Consequently, these agents should be positioned as adjunctive or investigational rather than as evidence-based treatments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148647693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple-Blind, Placebo-Controlled Trial","authors":"Anahid Rezaeifar,&nbsp;Mahtab Motamed,&nbsp;Niayesh Mohebbi","doi":"10.1002/hup.70057","DOIUrl":"10.1002/hup.70057","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This randomized, triple-blind, placebo-controlled clinical trial evaluated the efficacy and safety of quercetin in adults with autism spectrum disorder (ASD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty-two adults with ASD were randomly assigned to receive either quercetin or placebo for 60 days. Outcomes included the Social Responsiveness Scale (SRS), WHO Quality of Life (WHOQOL) domains, and other clinical measures assessed at baseline, 30 days, and 60 days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Baseline demographic characteristics and comorbid conditions were comparable between groups. The quercetin group showed a significant within-group reduction in SRS scores over time (<i>p</i> = 0.010), whereas the placebo group showed no significant change (<i>p</i> = 0.655). However, between-group differences in SRS change were not statistically significant. At week 8, the physical health domain of WHOQOL improved more in the quercetin group at the unadjusted level (<i>p</i> = 0.044), but this was not significant after adjustment (<i>p</i> = 0.082). The environmental health domain showed a borderline difference favoring quercetin (adjusted <i>p</i> = 0.053).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Quercetin supplementation showed potential benefits in select social quality of life and social domain responsiveness in participants with ASD. Larger, well-designed trials are needed to confirm its clinical effectiveness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>IRCT20241214064050N1</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Oculomotor Function Following Sleep Improvement With Lemborexant in Older Adults With Insomnia","authors":"Seiko Miyata,&nbsp;Keita Kawai,&nbsp;Kunihiro Iwamoto,&nbsp;Ippei Okada,&nbsp;Nao Matsuyama,&nbsp;Emiko Shishido,&nbsp;Kenichiro Miura,&nbsp;Akihiro Fujimoto,&nbsp;Yuki Kogo,&nbsp;Hiroshige Fujishiro,&nbsp;Ryota Hashimoto,&nbsp;Masashi Ikeda,&nbsp;Norio Ozaki","doi":"10.1002/hup.70056","DOIUrl":"10.1002/hup.70056","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Insomnia impairs cognitive and brain function, and its treatment improves outcomes. Eye movements are objective biomarkers of neurocognitive state and are sensitive to sleep loss, but whether treatment improves oculomotor function remains unclear. We examined associations between sleep improvement and eye movement changes after hypnotic intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this open-label, single-arm study, 31 Japanese adults aged ≥ 50 years with insomnia and preserved cognition received nightly lemborexant (5–10 mg) and were assessed at baseline, week 4, and week 12. Eye movements were measured using free-viewing, smooth pursuit, and fixation tasks. Objective sleep was assessed with a portable electroencephalogram, and subjective sleep and sleepiness with the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS). Associations were analyzed using linear mixed-effects models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Improvements in ESS and PSQI scores were associated with enhanced visual search performance in the free-viewing task, including increased saccade amplitude, scanpath length, and velocity. ESS improvement correlated with better tracking accuracy during smooth pursuit, reflected by fewer gaze fixations and saccades. Longer total sleep duration was associated with increased saccade duration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Selected eye movement metrics were modestly associated with improvements in subjective sleep symptoms following hypnotic treatment in older adults with insomnia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148383442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Clozapine Levels and Adverse Effects Evaluated by the GASS-C in Treatment-Resistant Schizophrenia","authors":"Yui Okubo,&nbsp;Hitoki Hirose,&nbsp;Shohei Nishimon,&nbsp;Hitoshi Maeshima","doi":"10.1002/hup.70055","DOIUrl":"10.1002/hup.70055","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia. However, evidence regarding whether adverse effects are related to the clozapine concentration is insufficient.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients treated with clozapine for at least 6 weeks and maintained on a fixed dose for &gt; 1 week were included (<i>n</i> = 47). Adverse effects were assessed using the self-rated Glasgow Antipsychotic Side-effects Scale for Clozapine (GASS-C). Plasma concentrations of clozapine and norclozapine were measured, and the relationship between the GASS-C score and clozapine concentration was analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Clozapine concentration was significantly associated with both the GASS-C score (rs = 0.435, <i>p</i> = 0.002) and norclozapine concentration (rs = 0.363 <i>p</i> = 0.012). In addition, significant correlations with large effect sizes were found for GASS-C sub-items such as hypersalivation and anticholinergic symptoms. Multiple regression indicated that the GASS-C total score was associated with both clozapine (<i>β</i> = 0.374, <i>p</i> = 0.012) and norclozapine (<i>β</i> = 0.404, <i>p</i> = 0.005) concentrations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Adverse effects, including subjective ones, of clozapine may be concentration-related and clinically important. However, monitoring clozapine levels may only have a supplementary role in managing its subjective adverse effects because subjective GASS-C scores could be influenced by psychological factors and patient perception, which may not always correlate linearly with pharmacokinetic data.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADHD, Psychotropic Medication and Pregnancy: The Influence of Maternal ADHD on Child Development—A Retrospective Cohort Study","authors":"Bregje Eleonore Elisabeth Maria Bonenkamp,&nbsp;Elvera Andrea Damer,&nbsp;Peter Gerrit Johannes ter Horst","doi":"10.1002/hup.70054","DOIUrl":"10.1002/hup.70054","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Attention Deficit/Hyperactivity Disorder (ADHD) is increasingly diagnosed in adults, including women of childbearing age. However, limited research exists on how maternal ADHD and psychotropic medication use during pregnancy impact early child development. This study aimed to assess developmental outcomes in children of mothers with ADHD during the first 4 years of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Setting</h3>\u0000 \u0000 <p>A retrospective cohort study using data from a pilot study, supplemented with data from Isala Hospital Zwolle (a general teaching hospital) and regional child health clinics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Participants</h3>\u0000 \u0000 <p>The exposed group comprised mothers diagnosed with ADHD, aged ≥ 18 years at term, with a gestation of ≥ 24 weeks. A subgroup used psychotropic medication during pregnancy (including SSRIs, methylphenidate, benzodiazepines and antipsychotics). The reference group included mothers without psychiatric diagnosis. Relevant somatic and socioeconomic confounders were documented.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Outcome</h3>\u0000 \u0000 <p>Child development was assessed using the Van Wiechen Onderzoek (VWO), a validated Dutch screening tool for early childhood developmental disorders, routinely used in child health clinics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-two children born to mothers with ADHD were included, of whom 36 were exposed to psychotropic medication in utero. Thirty-two children formed the reference group. Univariate analysis revealed no significant differences in total VWO-scores between children of mothers with and without ADHD, nor between those exposed and unexposed to psychotropic medication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Maternal ADHD and associated medication use during pregnancy did not appear to adversely affect early childhood development. However, findings are limited by the small sample size and should be interpreted with caution.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Trends in Prescribing of Etizolam for Hypnotic Use in a Japanese University Hospital","authors":"Mutsuhiro Nakao,&nbsp;Hokuto Morohoshi,&nbsp;Yumiko Kurata,&nbsp;Akiou Nakamura","doi":"10.1002/hup.70053","DOIUrl":"10.1002/hup.70053","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Etizolam is a short-acting thienodiazepine widely prescribed for anxiety and insomnia despite increasing concerns regarding dependence and guideline recommendations limiting long-term benzodiazepine use. This study examined long-term prescribing trends of etizolam compared with benzodiazepine and non-benzodiazepine hypnotics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective database study including 16,886,524 prescriptions issued between April 2001 and March 2022 at a tertiary university hospital in Japan. Seventeen hypnotic agents were identified (10 benzodiazepines and 7 non-benzodiazepines). Multivariable logistic regression was used to identify factors associated with prescribing hypnotic etizolam versus non-benzodiazepine hypnotics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 124,179 etizolam prescriptions, 83,927 (67.6%) were issued for hypnotic use. Although the absolute number of prescriptions declined over time, the proportion prescribed for hypnotic use remained stable. The ratio of hypnotic etizolam prescriptions to non-benzodiazepine hypnotics was higher in internal medicine than in psychiatry. In multivariable analysis, prescribing hypnotic etizolam was independently associated with internal medicine (adjusted OR 1.57), female sex, outpatient status, younger age, and earlier calendar year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite declining overall use, etizolam continues to be prescribed as a hypnotic, particularly in non-psychiatric settings. These findings highlight the persistence of specialty-specific prescribing patterns and underscore the importance of targeted educational and policy interventions to promote safer hypnotic prescribing practices.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70053","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Verbal and Visuospatial Working Memory Performance During the CO2 Challenge Model of Anxiety","authors":"Warren Dunger,&nbsp;Marc Edwards,&nbsp;Alex Board,&nbsp;Matthew Garner","doi":"10.1002/hup.70051","DOIUrl":"10.1002/hup.70051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Anxiety influences working memory performance, but the effects on clinical neuropsychological assessments of working memory are not well known.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We examined the effect of anxiety, induced using the 7.5% carbon dioxide model of anxiety on standardized clinical neuropsychological tests of working memory and executive function in a single-blind, placebo-controlled, randomized, crossover within-subjects design.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The CO₂-challenge reduced spatial working memory performance and verbal working memory performance accuracy when task demands were high. The CO₂-challenge increased effort and reduced processing efficiency across all verbal and spatial working memory tasks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The CO₂-challenge resulted in significant reductions in working memory performance and processing efficiency. These results encourage the routine assessment of anxiety when administering and interpreting neuropsychological measures of working memory function in clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148298816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Galectin-1 and Galectin-3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder","authors":"Büşra Sultan Sevindik,&nbsp;Özlem Olguner Eker,&nbsp;Akif Asdemir,&nbsp;Esra Kısacık,&nbsp;Ayşe Işık,&nbsp;Eser Kılıç,&nbsp;Ertuğrul Eşel","doi":"10.1002/hup.70052","DOIUrl":"https://doi.org/10.1002/hup.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Neuroinflammation is increasingly recognized as a key mechanism in the pathophysiology of Major Depressive Disorder (MDD). Galectin-1 and Galectin-3, <i>β</i>-galactoside-binding lectins involved in immune regulation and neuroprotection, may serve as biomarkers linking inflammation to cognitive dysfunction. However, no previous study has simultaneously examined serum levels of these galectins alongside detailed cognitive assessments in MDD. This study aimed to determine whether Galectin-1 and Galectin-3 are altered in MDD and to explore their association with disease severity and cognitive performance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Forty patients with MDD and 40 matched healthy controls were assessed. Depressive and anxiety symptoms were measured using the Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales. Cognitive performance was evaluated with the Rey Auditory Verbal Learning Test, Go/No-Go Test, and Stroop Test. Serum Galectin-1, Galectin-3, Glomerular Filtration Rate (GFR), and C-reactive protein (CRP) levels were determined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Serum Galectin-1 and Galectin-3 levels were significantly lower in the MDD group compared to controls (<i>p</i> &lt; 0.05). Galectin-1 levels showed a negative correlation with HAM-D and HAM-A scores, indicating an inverse association with symptom severity (i.e., lower Galectin-1 levels were associated with higher symptom severity). Patients exhibited impaired verbal learning, while no significant group differences were found in Go/No-Go or Stroop performance. Galectin levels did not correlate with any cognitive test scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Reduced Galectin-1 and Galectin-3 levels in MDD support their involvement in neuroinflammatory mechanisms. The inverse association between Galectin-1 and symptom severity suggests that Galectin-1 may be associated with symptom severity; however, the direction of this relationship remains unclear. The lack of associations with cognitive performance implies that cognitive deficits in MDD may be mediated by other immunometabolic pathways. These findings highlight galectins as promising but complex biomarkers, warranting further investigation in larger and longitudinal studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 3","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"41 3","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}